Molecular Templates (MTEM) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MTEM vs. AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, INCY, NBIX, and EXELShould you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Molecular Templates vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis Amgen (NASDAQ:AMGN) and Molecular Templates (NASDAQ:MTEM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership. Do analysts rate AMGN or MTEM? Amgen currently has a consensus target price of $309.22, suggesting a potential upside of 4.36%. Given Amgen's stronger consensus rating and higher possible upside, research analysts clearly believe Amgen is more favorable than Molecular Templates.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.38Molecular Templates 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to AMGN or MTEM? In the previous week, Amgen had 57 more articles in the media than Molecular Templates. MarketBeat recorded 57 mentions for Amgen and 0 mentions for Molecular Templates. Amgen's average media sentiment score of 1.39 beat Molecular Templates' score of 0.00 indicating that Amgen is being referred to more favorably in the media. Company Overall Sentiment Amgen Positive Molecular Templates Neutral Do insiders and institutionals hold more shares of AMGN or MTEM? 76.5% of Amgen shares are held by institutional investors. Comparatively, 95.5% of Molecular Templates shares are held by institutional investors. 0.8% of Amgen shares are held by company insiders. Comparatively, 13.9% of Molecular Templates shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, AMGN or MTEM? Amgen has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Does the MarketBeat Community believe in AMGN or MTEM? Amgen received 1217 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 71.71% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes155971.71% Underperform Votes61528.29% Molecular TemplatesOutperform Votes34267.32% Underperform Votes16632.68% Which has higher earnings and valuation, AMGN or MTEM? Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$34.13B4.67$4.09B$10.9627.03Molecular Templates$23.48M0.00-$8.12M-$2.70N/A Is AMGN or MTEM more profitable? Amgen has a net margin of 12.24% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 176.32% beat Molecular Templates' return on equity.Company Net Margins Return on Equity Return on Assets Amgen12.24% 176.32% 11.71% Molecular Templates -61.35%-260.50%-46.90% SummaryAmgen beats Molecular Templates on 15 of the 18 factors compared between the two stocks. Get Molecular Templates News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEM vs. The Competition Export to ExcelMetricMolecular TemplatesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$6.92B$5.61B$8.62BDividend YieldN/A2.54%5.28%4.17%P/E Ratio0.008.6727.1419.96Price / SalesN/A262.53414.30157.63Price / CashN/A65.8538.2534.64Price / BookN/A6.597.074.69Net Income-$8.12M$143.75M$3.23B$248.14M Molecular Templates Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.4744 of 5 stars$288.47+0.1%$309.22+7.2%-1.3%$155.11B$34.13B38.2125,200Positive NewsAnalyst RevisionGILDGilead Sciences4.878 of 5 stars$108.91-1.1%$110.55+1.5%+74.2%$135.48B$28.74B294.3517,000Positive NewsOptions VolumeAnalyst RevisionVRTXVertex Pharmaceuticals4.6563 of 5 stars$445.43+0.8%$515.04+15.6%-3.3%$114.39B$11.10B-202.474,800Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.9038 of 5 stars$490.81+0.1%$847.40+72.7%-49.2%$52.99B$14.09B12.8211,900Positive NewsAnalyst RevisionHigh Trading VolumeALNYAlnylam Pharmaceuticals4.2821 of 5 stars$306.09+0.5%$319.17+4.3%+91.6%$39.91B$2.35B-141.052,000Positive NewsAnalyst ForecastBIIBBiogen4.6977 of 5 stars$131.14+1.0%$191.30+45.9%-42.6%$19.22B$9.82B11.728,720Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.9935 of 5 stars$325.48+2.1%$393.00+20.7%+1.5%$14.68B$2.99B14.29980Positive NewsAnalyst ForecastInsider TradeAnalyst RevisionINCYIncyte4.544 of 5 stars$65.31+0.4%$73.60+12.7%+15.5%$12.64B$4.41B241.902,320Positive NewsNBIXNeurocrine Biosciences4.8979 of 5 stars$124.56+1.3%$162.00+30.1%-7.1%$12.33B$2.41B37.861,200Analyst RevisionEXELExelixis4.5386 of 5 stars$42.88-0.4%$38.94-9.2%+89.4%$11.69B$2.30B24.231,220Positive NewsAnalyst Forecast Related Companies and Tools Related Companies AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEM) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
